WHO calls ethics meeting over experimental Ebola drug

Image
AFP Geneva
Last Updated : Aug 07 2014 | 12:30 AM IST
The World Health Organization said today it was convening an ethics meeting next week to explore the use of experimental treatment in the Ebola outbreak in West Africa.
The move comes after two health workers from the US charity Samaritan's Purse were treated with medication that the WHO said had never been tested and shown to be safe in people.
"We are in an unusual situation in this outbreak. We have a disease with a high fatality rate without any proven treatment or vaccine," said Marie-Paule Kieny, assistant director-general of the UN health agency.
"We need to ask the medical ethicists to give us guidance on what the responsible thing to do is," she said in a statement.
Samaritan's Purse members Kent Brantly and Nancy Writebol were stricken with Ebola while treating patients in Liberia.
The patients, who were rushed to the United States amid tight medical security, were reportedly given an experimental drug known as ZMapp.
Both have shown improvements in their health and are now being treated in isolation at an Atlanta, Georgia hospital.
There is currently no registered medicine or vaccine against the Ebola virus -- which in the past has shown fatality rates approaching 90 percent -- but there are several experimental options under development.
The WHO said experimental drugs raised questions about whether they should be deployed during such an outbreak and, given the extremely limited amount available, who should receive them if they were used.
"The gold standard for assessing new medicine involves a series of trials in humans, starting small to make sure the medicine is safe to use. Then, the studies are expanded to more people to see how effective it is, and how best to use it," said the WHO.
"The guiding principal with use of any new medicine is 'do no harm'. Safety is always the main concern," it added.
The Ebola virus causes fever, vomiting, diarrhoea, muscle aches and sometimes organ failure and hemorrhaging.
The ongoing outbreak in West Africa is the deadliest in history, having killed 932 of the more than 1,700 infected.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 07 2014 | 12:30 AM IST

Next Story